ICECURE MEDICAL LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7356 USD | -1.31% |
|
-10.18% | -31.25% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 109.1 | 70.72 | 48.84 | 35.26 | - | - |
| Enterprise Value (EV) 1 | 109.1 | 70.72 | 48.84 | 35.26 | 35.26 | 35.26 |
| P/E ratio | - | -3.37 x | -3.34 x | -2.63 x | -2.79 x | -36.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 26.4 x | 22.9 x | 15.1 x | 8.89 x | 4.43 x | 1.04 x |
| EV / Revenue | 26.4 x | 22.9 x | 15.1 x | 8.89 x | 4.43 x | 1.04 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | -4.66 x | -3.76 x | -2.43 x | -2.98 x | -2.93 x |
| FCF Yield | - | -21.5% | -26.6% | -41.2% | -33.5% | -34.2% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,780 | 45,623 | 45,642 | 47,939 | - | - |
| Reference price 2 | 3.050 | 1.550 | 1.070 | 0.7356 | 0.7356 | 0.7356 |
| Announcement Date | 01/04/22 | 29/03/23 | 03/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 4.138 | 3.085 | 3.229 | 3.966 | 7.966 | 33.87 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -9.724 | -16.74 | -15.58 | -13.55 | -13.33 | -0.875 |
| Operating Margin | - | -234.99% | -542.59% | -482.38% | -341.67% | -167.35% | -2.58% |
| Earnings before Tax (EBT) 1 | - | - | -16.98 | -14.65 | -13.14 | -13.31 | -1.075 |
| Net income 1 | -4.528 | - | -16.98 | -14.65 | -13.48 | -13.34 | -1.075 |
| Net margin | - | - | -550.34% | -453.76% | -339.94% | -167.5% | -3.17% |
| EPS 2 | - | - | -0.4600 | -0.3200 | -0.2800 | -0.2633 | -0.0200 |
| Free Cash Flow 1 | - | - | -15.18 | -13 | -14.52 | -11.83 | -12.04 |
| FCF margin | - | - | -492.16% | -402.63% | -366.11% | -148.47% | -35.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 25/03/21 | 01/04/22 | 29/03/23 | 03/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.073 | 0.765 | 0.634 | 0.939 | 0.71 | 0.937 | 0.327 | 1.255 | 0.743 | 0.9255 | 0.7885 | 1.242 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -4.281 | -4.101 | -3.932 | -3.957 | -4.081 | -4.123 | -3.415 | -3.65 | -3.558 | -3.592 | -3.554 | - |
| Operating Margin | - | -559.61% | -646.85% | -418.74% | -557.32% | -435.54% | -1,260.86% | -272.11% | -491.25% | -384.39% | -455.61% | -286.08% | - |
| Earnings before Tax (EBT) 1 | - | - | -4.058 | -3.952 | -3.768 | -3.889 | -4 | -2.995 | -3.609 | -3.59 | -3.67 | -3.47 | - |
| Net income 1 | 3.847 | - | -4.058 | -3.952 | -3.768 | -3.889 | -4 | -2.995 | -3.609 | -3.537 | -3.572 | -3.534 | - |
| Net margin | 185.58% | - | -640.06% | -420.87% | -530.7% | -415.05% | -1,223.24% | -238.65% | -485.73% | -382.17% | -453.01% | -284.43% | - |
| EPS 2 | 0.1560 | - | -0.1100 | -0.1060 | -0.0800 | -0.0880 | -0.0870 | -0.0600 | -0.0800 | -0.0700 | -0.0700 | -0.0750 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 23/09/21 | 15/08/22 | 05/12/22 | 29/03/23 | 22/05/23 | 14/08/23 | 15/11/23 | 03/04/24 | 28/05/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -15.2 | -13 | -14.5 | -11.8 | -12 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 0.89 | 0.48 | 0.25 | 0.25 | 0.25 |
| Capex / Sales | - | - | 28.88% | 14.87% | 6.3% | 3.14% | 0.74% |
| Announcement Date | 25/03/21 | 01/04/22 | 29/03/23 | 03/04/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7356
USD
Average target price
3.387
USD
Spread / Average Target
+360.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.25% | 35.26M | |
| +6.37% | 216B | |
| +10.21% | 189B | |
| +28.22% | 153B | |
| +34.42% | 114B | |
| +0.99% | 63.2B | |
| +19.21% | 54.78B | |
| +0.13% | 48.47B | |
| -4.16% | 38.88B | |
| +2.39% | 36.14B |
- Stock Market
- Equities
- ICCM Stock
- Financials IceCure Medical Ltd
